Estimation of population characteristics of pharmacokinetic parameters from routine clinical data
about
Recommended reading in population pharmacokinetic pharmacodynamicsIntravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic studyPharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireviewLewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice VersaPopulation analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyApplication of NONMEM to routine bioavailability data.Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats.Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbitsEstimation of pharmacokinetic parameters based on the patient-adjusted population data.Applications of population pharmacokinetics in current drug labelling.Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients.Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid.Translational learning from clinical studies predicts drug pharmacokinetics across patient populations.Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.Statistical analysis of pharmacokinetic data.Interspecies mixed-effect pharmacokinetic modeling of penicillin G in cattle and swineCitalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.Population pharmacokinetics of quinidine.Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension.Evaluation of a microcomputer program (OPT) for parameter optimisation in clinical pharmacokinetics: gentamicin and tobramycin.The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.Re-examination of digoxin dosage regimen: comparison of the proposed nomograms or formulae in elderly patients.Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction.Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic studyPerformance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy.Clinical pharmacology = disease progression + drug actionInterpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies
P2860
Q24647906-004787AD-3883-4CAF-B8CE-E1C5BD5E588EQ24679028-D8FB70BE-2705-430C-969F-D296DF514B8AQ27025071-7F5991FA-3343-4F7F-9E67-0074093E03A8Q28652486-D337E068-E468-43FE-BDE0-CD596E22EB48Q30443910-83FCE45F-E3CA-4864-813D-06D9E1F02C80Q30597644-E39757D9-EB8C-4D35-A854-2BFEE8242A20Q30747608-FABA214B-81A2-4C20-8F87-C5265614DB55Q30827141-16251CA4-E1FF-4F6A-9ACC-002258FF9E3AQ30841916-ECF01E31-64BB-4F40-BFDF-4BE7DDBC28B2Q30895231-1DA45328-70C4-499D-96ED-A31BF99129B4Q30990291-843CEE20-9175-4188-8384-AE98BA776AB2Q31082856-93A1743E-3AEA-4C1E-B322-6A1DC90FCFEEQ33272641-795DFEA3-972E-4DE6-B592-007202C98110Q33392206-59DE890F-3EFA-48AC-8CDF-E8918FFA69AEQ33553063-5078E74D-CA70-4AEF-BFE1-F734215024C1Q33668845-8D79F2EF-204A-4C5D-9901-CA165E970725Q33693467-E94160BF-6599-4F48-AAE5-91AD6923A2FAQ33695250-5C682B9F-56BB-436D-B25C-2858E466615FQ33758961-7134E8E7-04FE-4927-8975-B98537EE4825Q33767468-812F68EE-651B-4C47-95CA-174355978791Q33928776-3260A397-3AFF-4B55-A051-43ED1A048F9EQ34051009-704BF5FF-41A7-4072-9F43-0CFEA6559AD1Q34058378-8EDA4F71-8571-4D9D-9A16-DE5539C1F2B3Q34065310-D37D67D8-62D2-4B4E-BAB5-253DA0DBF854Q34145251-F6C82651-C1FA-4070-B362-77CF1DECC2A5Q34211026-06F78826-9B24-4361-8F3A-D82948584367Q34358018-75980265-CF32-45E2-A68A-83C64C01A9AAQ34376951-A136DBBB-AEFB-4756-81FB-91A184F3E9BCQ34393200-B3A3A36B-1196-48E1-9588-5735572D3E44Q34396973-0CADDEFC-3BE4-47E5-9181-196338A54DC1Q34417050-C956FC0C-0B28-4AA7-B416-64645EDE20AAQ34448528-24E2D5D5-E0EB-41C2-BA4E-71583DB2BD4FQ34449966-9E04D28A-63CA-4BEF-87A6-2AEF9B6B7601Q34518779-6DBC4733-F6DA-41A3-B4AF-0EBE6658BF64Q34626158-0DA2090B-357B-4D75-A578-87A4E1BFE2DFQ34879068-172644EC-9590-4BFB-B3C7-629F703F122CQ34953659-D4ED854C-C56F-4933-9DFF-D62D9F432DD9Q34996894-49CA8BB3-D9BE-412B-8548-690EC5981D3AQ35116889-664AD1C4-9BBA-4368-94A3-D35A9F513600Q35122861-120D9945-EAB5-4712-8CDB-1927FEB773A9
P2860
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data
description
1977 nî lūn-bûn
@nan
1977 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Estimation of population chara ...... ers from routine clinical data
@ast
Estimation of population chara ...... ers from routine clinical data
@en
Estimation of population chara ...... ers from routine clinical data
@nl
type
label
Estimation of population chara ...... ers from routine clinical data
@ast
Estimation of population chara ...... ers from routine clinical data
@en
Estimation of population chara ...... ers from routine clinical data
@nl
prefLabel
Estimation of population chara ...... ers from routine clinical data
@ast
Estimation of population chara ...... ers from routine clinical data
@en
Estimation of population chara ...... ers from routine clinical data
@nl
P2093
P2860
P356
P1476
Estimation of population chara ...... ers from routine clinical data
@en
P2093
B Rosenberg
L B Sheiner
V V Marathe
P2860
P2888
P304
P356
10.1007/BF01061728
P407
P577
1977-10-01T00:00:00Z
P6179
1045288191